^
Association details:
| Biomarker: | VHL mutation |
|---|---|
| Cancer: | Neuroendocrine Tumor |
| Drug: | MK-3795 (HIF-2α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RESULTS OF AN OPEN LABEL PHASE II CLINICAL TRIAL OF A HIF-2ALPHA INHIBITOR (PT2385) IN VON HIPPEL-LINDAU ASSOCIATED CLEAR CELL RENAL CELL CARCINOMA.
Published date:
11/20/2020
Excerpt:
PT2385 was administered orally at a dose of 800 mg twice daily….VHL manifestations in other organ systems (hemangioblastoma, pancreatic neuroendocrine tumor) remained stable or improved.
Trial ID:
